{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:36:11Z","timestamp":1790912171402,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.clml.2024.01.011","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T19:43:04Z","timestamp":1706125384000},"page":"e191-e195.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed\/Refractory Follicular Lymphoma"],"prefix":"10.1016","volume":"24","author":[{"given":"Paola","family":"Ghione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markqayne D.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-8030","authenticated-orcid":false,"given":"Eve H.","family":"Limbrick-Oldfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Kanters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Bobillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Ribiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrna","family":"Nahas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Beygi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anik R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.01.011_bib0001","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.1182\/blood-2022-170469","article-title":"A 3-year follow-up comparison of clinical outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 external control cohort in relapsed\/refractory follicular lymphoma (R\/R FL) [abstract]","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.01.011_bib0002","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3324\/haematol.2021.278717","article-title":"Prospects in the management of patients with follicular lymphoma beyond first-line therapy","volume":"107","author":"Qualls","year":"2022","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2024.01.011_bib0003","doi-asserted-by":"crossref","first-page":"e745","DOI":"10.1097\/HS9.0000000000000745","article-title":"A retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (ReCORD-FL)","volume":"6","author":"Salles","year":"2022","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.clml.2024.01.011_bib0004","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2022.281421","article-title":"Treatment patterns and outcomes in relapsed\/refractory follicular lymphoma: results from the international SCHOLAR-5 study","volume":"108","author":"Ghione","year":"2022","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.01.011_bib0005","first-page":"40","article-title":"Primary analysis of Zuma-5: A phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL) [abstract]","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.01.011_bib0006","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.01.011_bib0007","unstructured":"Food aDA. FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma 2021 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-axicabtagene-ciloleucel-relapsed-or-refractory-follicular-lymphoma. Available November 1, 2023."},{"key":"10.1016\/j.clml.2024.01.011_bib0008","unstructured":"European MA. EMA Recommends Extension of Therapeutic Indications for Axicabtagene Ciloleucel 2022 [Available from: https:\/\/www.esmo.org\/oncology-news\/ema-recommends-extension-of-indications-for-axicabtagene-ciloleucel#:\u223c:text=On%2015%20September%202022%2C%20the,product%20axicabtagene%20ciloleucel%20(Yescarta). Available November 1, 2023."},{"issue":"8","key":"10.1016\/j.clml.2024.01.011_bib0009","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2021014375","article-title":"Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"140","author":"Ghione","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.01.011_bib0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/14737140.2023.2171994","article-title":"A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma","volume":"23","author":"Palomba","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"10.1016\/j.clml.2024.01.011_bib0011","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.clml.2024.01.011_bib0012","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.01.011_bib0013","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.clml.2024.01.011_bib0014","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.clml.2024.01.011_bib0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clml.2023.09.007","article-title":"Indirect treatment comparisons of mosunetuzumab with third- and later-line treatments for relapsed\/refractory follicular lymphoma","volume":"24","author":"Bosch","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.01.011_bib0016","unstructured":"NIH: USNLoM. Study of axicabtagene ciloleucel versus standard of care therapy in participants with relapsed\/refractory follicular lymphoma (ZUMA-22) 2023 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05371093. Available November 1, 2023."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000557?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024000557?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:32Z","timestamp":1761871412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024000557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2152265024000557"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed\/Refractory Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}